← boardnext 2028-01
ARTV
Artiva Biotherapeutics, Inc.distress 2/10 · well-funded / low risk$9.36-7%today-30% from 52w high
Oncology 1
Lead: refractory rheumatoid arthritis · target CD20 · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$140M
Runway
1.8 yrs
Shares 1y
+1%
Price & events
+89.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-6.6%
1D
+3.5%
1W
-4.5%
1M
-17.2%
3M
+95.7%
6M
+191.4%
1Y
-22.1%
2Y
—
5Y
-22.0%
All
Overview
- Market Cap
- $231.22M
- Volume
- 29.33K
- 52 Week Range
- $2.04 – $13.39
- Total Shares
- 24.72M
- Float Shares
- 10.01M
- Short %
- 3.94%
- % Held by Insiders
- 14.14%
- % Held by Institutions
- 51.58%
- RVOL
- 0.05x
- Beta
- 2.19
Pipeline stages · 2 programs
Allogeneic NK Cells
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AB-101, Rituximab, Interleukin-2CD20
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-01 Estimated 50% readout ~2028-02-15 | Phase 2 | Allogeneic NK Cells | Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease | — | recruiting |
| 2025-10-06 | Phase 1/2 | AB-101, Rituximab, Interleukin-2 | Non Hodgkin Lymphoma | 45 | completed |
Catalyst news & presentations · 5
- 2029Guided 40%regulatory submissionFiled (NDA/BLA)AlloNK · Potential BLA submission for AlloNK in refractory RASEC 8-K
- second half of 2028Guided 55%readoutPhase 3AlloNK · Report primary efficacy data from Phase 3 trialSEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 3AlloNK · Initiate Phase 3 registrational trial of AlloNK plus rituximab in refractory RASEC 8-K
- first half of 2026readoutPhase 1/2AlloNK (AB-101) · Share initial clinical response data across dose levels from >15 refractory RA patients.SEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)AlloNK (AB-101) · Conduct FDA regulatory interactions to align on potential pivotal trial design.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-08NeedhamBuy
- 2026-05-12NeedhamBuy
- 2026-05-11Cantor FitzgeraldOverweight
- 2026-05-11WedbushOutperform
- 2026-05-08HC Wainwright & Co.Buy
- 2026-05-04NeedhamBuy
Competitors — CD20
Recent news
- 2026-07-23ARTV Options Chain — NASDAQ:ARTV - TradingView
- 2026-07-22Artiva Biotherapeutics Sets Deadline for 2026 Meeting - TipRanks
- 2026-07-22Artiva sets 2026 annual meeting for Sept. 8; stockholder notice deadline Aug. 1 - TradingView
- 2026-07-22Artiva Biotherapeutics (Nasdaq: ARTV) details 2026 meeting deadlines - Stock Titan
- 2026-07-21Major Insider Move Signals Growing Confidence in Artiva Biotherapeutics - TipRanks
- 2026-07-17$ARTV stock is up 9% today. Here's what we see in our data. - Quiver Quantitative
- 2026-07-17Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
- 2026-07-17Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.